For years, every time there was a controversial decision in biopharma, an interesting discovery in chemistry, or an oversupply of enthusiasm for an idea or technology, Derek Lowe often has had something to say.
From his blog at Science, he has written hundreds of posts on what the drug industry is thinking and talking about. And today he’s going to be joining us on Post-Hoc Live to chat about his writing career, some of his recent posts on Sarepta, and his thoughts on a few big ideas in chemistry.
Derek joined us on YouTube.
This was a conversation I’ve wanted to have for a long time, and I was joined by our senior biopharma correspondent Andrew Dunn, who has written about Lowe's work outside his blog as an advisor to the AI company Iambic Therapeutics.
Thanks for watching!
— Drew
↧